柏 方,陈 青,吴克瑾.GP方案与NP方案治疗晚期乳腺癌疗效的Meta分析[J].肿瘤学杂志,2016,22(4):259-264. |
GP方案与NP方案治疗晚期乳腺癌疗效的Meta分析 |
Clinical Observation of GP and NP Regimen in the Treatment for Advanced Breast Cancer:A Meta-analysis |
投稿时间:2015-10-29 |
DOI:10.11735/j.issn.1671-170X.2016.04.B002 |
|
|
中文关键词: 乳腺肿瘤 吉西他滨 顺铂 长春瑞滨 疗效 Meta分析 |
英文关键词:breast neoplasms gemcitabine cisplatin vinorelbine response Meta-analysis |
基金项目:上海市科学技术委员会科研计划项目(14411950206) |
|
摘要点击次数: 1743 |
全文下载次数: 989 |
中文摘要: |
摘 要:[目的] 利用Meta分析研究吉西他滨联合顺铂(GP方案)及长春瑞滨联合顺铂(NP方案)治疗晚期乳腺癌的疗效。[方法] 计算机检索万方数据库、中国知网数据库、PubMed、Cochrane Library,纳入GP方案及NP方案治疗晚期乳腺癌的随机对照研究,检索时间为2004年1月至2015年8月。由 2 名评价员按纳入与排除标准独立筛选文献、 提取资料并评价纳入研究的方法学质量后,所有数据均用RevMan5.2软件处理。[结果] 共纳入14个RCT,其中GP组545例,NP组547例。Meta分析结果显示,两组反应率(RR)(OR=1.19,95%CI:0.94~1.52)及疾病控制率(DCR)(OR=1.15,95%CI:0.87~1.53)无统计学差异。3级及以上不良反应包括白细胞减少症、血小板减少症、恶心呕吐、静脉炎。Begg漏斗图未发现发表偏倚。[结论] GP及NP方案对提高晚期乳腺癌患者RR及DCR的疗效肯定,临床效果相似,值得进一步研究。 |
英文摘要: |
Abstract:[Objective] To systematically review the efficacy of GP and NP regimen in the treatment for advanced breast cancer. [Methods] PubMed,Cochrane Library,CNKI and the Chinese Wangfang Database were searched from January 2004 to August 2015 for studies of GP and NP in advanced breast cancer patients. Two reviewers independently screened literature according to the exclusion and inclusion criteria,extracted data and assessed methodological quality of included studies. Then,meta-analysis was performed using RevMan 5.2 software. [Results] A total of 14 RCTs (involving 545 gemcitabine-cisplatin regimen cases and 547 vinorelbine-cisplatin regimen cases) were included. The results of meta-analysis showed that no significance was found between two groups in response rate(RR)(OR=1.19,95%CI:0.94~1.52)and disease control rate (DCR)(OR=1.15,95%CI:0.87~1.53). Grade 3 or greater adverse events included leukopenia,thrombocytopenia,nausea and vomit and phlebitis. In addition,no publication bias was found from Begg’s funnel plot. [Conclusions] The results of the current meta-analysis indicate that the efficacy of GP and NP regimen are good in advanced breast cancer patients for the improvement of RR or DCR. More evaluation may be considered to prove this theory. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |